| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803053501054 | 305350105 | ESPOZA F.C.TAB 5MG/TAB BTx20 (ALU/ALU blister) | 2.96 | 3.11 | 4.28 |
| 05/2018 | 2803053501061 | 305350106 | ESPOZA F.C.TAB 5MG/TAB BTx20 (Clear PVC-Aclar/ALU blister) | 2.65 | 2.78 | 3.83 |
| 05/2018 | 2803053501078 | 305350107 | ESPOZA F.C.TAB 5MG/TAB BTx50 (ALU/ALU blister) | 06.02 | 6.32 | 8.71 |
| 05/2018 | 2803053501085 | 305350108 | ESPOZA F.C.TAB 5MG/TAB BTx50 (Clear PVC-Aclar/ALU blister) | 06.02 | 6.32 | 8.71 |
| 05/2018 | 2803053501092 | 305350109 | ESPOZA F.C.TAB 5MG/TAB BTx100 (ALU/ALU blister) | 12.06 | 12.65 | 17.44 |
| 05/2018 | 2803053501108 | 305350110 | ESPOZA F.C.TAB 5MG/TAB BTx100 (Clear PVC-Aclar/ALU blister) | 12.06 | 12.65 | 17.44 |
| 05/2018 | 2803053502013 | 305350201 | ESPOZA F.C.TAB 10MG/TAB BTx14 (ALU/ALU blister) | 3.83 | 04.02 | 5.54 |
| 05/2018 | 2803053502037 | 305350203 | ESPOZA F.C.TAB 10MG/TAB BTx28 (ALU/ALU blister) | 5.40 | 5.66 | 7.80 |
| 05/2018 | 2803053503010 | 305350301 | ESPOZA F.C.TAB 15MG/TAB BTx28 (ALU/ALU blister) | 5.88 | 6.17 | 8.50 |
| 05/2018 | 2803053503034 | 305350303 | ESPOZA F.C.TAB 15MG/TAB BTx20 (ALU/ALU blister) | 5.20 | 5.45 | 7.52 |
| 05/2018 | 2803053503041 | 305350304 | ESPOZA F.C.TAB 15MG/TAB BTx20 (Clear PVC-Aclar/ALU blister) | 5.20 | 5.45 | 7.52 |
| 05/2018 | 2803053503058 | 305350305 | ESPOZA F.C.TAB 15MG/TAB BTx50 (ALU/ALU blister) | 12.82 | 13.45 | 18.54 |
| 05/2018 | 2803053503065 | 305350306 | ESPOZA F.C.TAB 15MG/TAB BTx50 (Clear PVC-Aclar/ALU blister) | 12.82 | 13.45 | 18.54 |
| 05/2018 | 2803053503072 | 305350307 | ESPOZA F.C.TAB 15MG/TAB BTx100 (ALU/ALU blister) | 25.64 | 26.90 | 37.07 |
| 05/2018 | 2803053503089 | 305350308 | ESPOZA F.C.TAB 15MG/TAB BTx100 (Clear PVC-Aclar/ALU blister) | 25.64 | 26.90 | 37.07 |
| 05/2018 | 2803053504024 | 305350402 | ESPOZA F.C.TAB 20MG/TAB BTx28 (ALU/ALU blister) | 9.57 | 10.04 | 13.83 |
| 05/2018 | 2803053504093 | 305350409 | ESPOZA F.C.TAB 20MG/TAB BTx14 (ALU/ALU blister) | 5.44 | 5.71 | 7.87 |
| 05/2018 | 2803053504109 | 305350410 | ESPOZA F.C.TAB 20MG/TAB BTx14 (Clear PVC-Aclar/ALU blister) | 5.44 | 5.71 | 7.87 |
For the treatment of depression.
The antidepressant, antiobsessive-compulsive, and antibulimic actions of Citalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Citalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT<sub>1A</sub> autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.
Symptoms most often accompanying citalopram overdose, alone or in combination with other drugs and/or alcohol, included dizziness, sweating, nausea, vomiting, tremor, somnolence, and sinus tachycardia. In more rare cases, observed symptoms included amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and very rare cases of torsade de pointes). Acute renal failure has been very rarely reported accompanying overdose.
Bioavailability is 80% following oral administration.
35 hours
The systemic clearance of citalopram was 330 mL/min, with approximately 20% of that due to renal clearance. Citalopram is metabolized to demethylcitalopram (DCT), didemethylcitalopram (DDCT), citalopram-N-oxide, and a deaminated propionic acid derivative.
* 12 L/kg
For the treatment of major depressive disorder and Generalized Anxiety Disorder (GAD).
The antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Escitalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT<sub>1A</sub> autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.
Signs of overdose include convulsions, coma, dizziness, hypotension, insomnia, nausea, vomiting, sinus tachycardia, somnolence, and ECG changes (including QT prolongation).
The absolute bioavailability of citalopram is about 80% relative to an intravenous dose
27-32 hours
Following oral administrations of escitalopram, the fraction of drug recovered in the urine as escitalopram and S-demethylcitalopram (S-DCT) is about 8% and 10%, respectively. The oral clearance of escitalopram is 600 mL/min, with approximately 7% of that due to renal clearance. Escitalopram is metabolized to S-DCT and S-didemethylcitalopram (S-DDCT).
* 12 L/kg
* oral cl=600 mL/min [Following oral administrations]